Formulation Development
Zealand Pharma Announces First Participant Enrolled in Phase 2b Trial of Petrelintide in People With Overweight or Obesity
Zealand Pharma A/S recently announced the first participant has been enrolled in ZUPREME-1, a global Phase 2b trial in people with obesity or overweight with…
Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate Toward Clinical Development
Eikonizo Therapeutics recently announced it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative. In addition to supporting the development…
Immutep Announces Initiation of Phase 3 Trial in First Line Non-Small Cell Lung Cancer
Immutep Limited recently announced the initiation of the pivotal TACTI-004 Phase 3 clinical trial for the treatment of first-line metastatic non-small cell lung cancer (1L…
Scienture Announces Issuance of New Patent Covering its First Product Losartan Potassium Oral Suspension Through 2041
SCIENTURE, LLC, a wholly owned subsidiary of SCIENTURE HOLDINGS, INC. recently announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent, No.…
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced additional clinical data from ongoing analyses of results from the…
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
NurExone Biologic Inc., a biopharmaceutical company developing exosome-based regenerative therapies, has announced significant findings from an expanded preclinical study of the potential of its portfolio…
Bionical Emas Sells EMAS Pharma to Kester Capital Following Strategic Review
Bionical Emas is selling its Clinical Development division, EMAS Pharma, to Kester Capital and an incoming executive team. The decision to sell comes after a…
Medigene AG Announces KRAS G12V as First Target for TCR-Guided T Cell Engagers
Medigene AG recently announced the selection of Kirsten rat sarcoma viral oncogene homologue (KRAS) G12V, in the context of HLA*A11, as the initial target for the…
Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial
Sonnet BioTherapeutics Holdings, Inc. recently announced that the results of SON-1010 at the highest dose have been formally evaluated by the Safety Review Committee in…
Mestag Therapeutics Announces Licensing of Novel Inflammatory Disease Target From its RAFT Platform
Mestag Therapeutics recently announced that Johnson & Johnson has exclusively licensed a novel, undisclosed target identified using Mestag’s Reversing Activated Fibroblast Technology (RAFT) platform under…
First FDA-Approved Treatment for Severe Frostbite Now Commercially Available in the US
SERB Pharmaceuticals recently announce Aurlumyn (iloprost) Injection, the first FDA-approved treatment for severe frostbite in adults to reduce the risk of digit amputations, is now…
CERo Therapeutics Appoints Chris Ehrlich CEO
CERo Therapeutics Holdings, Inc. recently announced its Board of Directors has appointed Chris Ehrlich as CEO. Previously he held the position of Interim CEO. Mr.…
Exclusive UniSafe Distribution Agreement Between Owen Mumford & NIPRO Exceeds Expectations in Japan With New Biosimilar Launch
Owen Mumford, a global leader in medical devices, recently announce its exclusive agreement with Osaka-based NIPRO CORPORATION (NIPRO) to distribute drug delivery device UniSafe® has…
World’s First Zero-Off-Target Base-Edited NK Cell Therapy Receives IND Approval in Both China & US
Base Therapeutics recently announced its NK510 cell injection, the world’s first zero-off-target base-edited NK cell product, has received IND approvals from both the US FDA…
TILT Biotherapeutics Provides Update on International Clinical Trial Progress With Intravenous Delivery Regimen for Cancer Immunotherapies
TILT Biotherapeutics (TILT) recently announced it will be presenting data at the European Society of Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2024. The oral presentation discloses…
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CG Oncology, Inc. recently announced topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus…
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
Denali Therapeutics Inc. recently announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich repeat kinase 2 (LRRK2)…
Samabriva Accelerates its Growth With New State-of-the-Art Biomanufacturing Facility
Samabriva recently announced the opening of a new 1,400 m² biomanufacturing facility in Liege, Belgium, at the heart of European’s biotech valley. This strategic investment…
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious US Medical Centers
Tiziana Life Sciences, Ltd. recently announced the expansion of its Phase 2 clinical trial evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis (SPMS). The…
8 Years Survival With Complete Cure for a Patient With Advanced Liver Cancer Being Treated With Namodenoson Drug
Can-Fite BioPharma Ltd. recently announced a patient currently treated with Namodenoson in a compassionate use program in Can-Fite’s Phase 2 Liver Cancer Study has an…